Nanotherapeutics for Alzheimer's disease (AD): Past, present and future.
Drug delivery to the brain still remains highly challenging for the treatment of Alzheimer's disease (AD). The development of new practical treatment modalities for the treatment of AD is currently a highly active area of research. Our lack of success in the development of effective therapies for AD is attributed to, but not limited to a number of factors including the complexity of the brain. Besides this, it is recognized that AD is multisystemic in nature and this presents numerous difficulties for the potential treatment of these disorders. Another important reason for the lack of development of effective drugs and drug delivery system for AD is inability to deliver drugs effectively to the brain due to the numerous protective barriers surrounding the CNS i.e. blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB) and circumventricular organs (CVOs). Solutions to these problems require enhanced novel research activities that can address each of these problems. This review article provides a concise movement into the current and future applications of nanoparticulate drug delivery systems for the treatment of AD and explores the application of nanotechnology in clinical neuroscience to develop innovative therapeutic modalities for the AD.
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
Mohammad
M
Fazil
Shadab
Sanjula
S
Baboota
Jasjeet K
JK
Sahni
Javed
J
Ali
D000544:Alzheimer Disease / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D053758:Nanoparticles / Q000009:adverse effects / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000627:therapeutic use; D008517:Phytotherapy / Q000379:methods
D018697:Nootropic Agents